<SEC-DOCUMENT>0001628280-26-033831.txt : 20260512
<SEC-HEADER>0001628280-26-033831.hdr.sgml : 20260512
<ACCEPTANCE-DATETIME>20260512060727
ACCESSION NUMBER:		0001628280-26-033831
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260512
FILED AS OF DATE:		20260512
DATE AS OF CHANGE:		20260512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231
		LEGAL ENTITY IDENTIFIER:    	9695002Y8420ZB8HJE29

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		26965700

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6k-iphx260512.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="icf35b237d85642fa97794bbe6e25ca5c_1"></div><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.55pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="margin-top:0.1pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-top:0.1pt;padding-left:199.2pt;padding-right:199.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:218%">Washington, D.C. 20549 FORM 6-K</font></div><div style="margin-top:0.5pt;padding-left:6.82pt;padding-right:6.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:240%">Date of report&#58; Tuesday May 12, 2026</font></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:240%">Commission File Number&#58; 001-39084</font></div><div style="margin-top:0.05pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Innate Pharma S.A.</font></div><div style="margin-top:0.45pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">(Translation of registrant's name into English)</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Innate Pharma S.A.</font></div><div style="margin-top:0.4pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">117 Avenue de Luminy&#8212;BP 30191</font></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">13009 Marseille, France</font></div><div style="margin-top:0.45pt;padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">+ 33 (0) 4 30 30 30</font></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">(Address of principal executive office)</font></div><div style="margin-top:0.25pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Indicate  by  check  mark  whether  the  registrant  files  or  will  file  annual  reports  under  cover  of  Form 20-F or Form 40-F. Form 20-F &#91; X &#93;&#160;&#160;&#160;&#160;Form 40-F &#91; &#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.45pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">EXHIBIT INDEX</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%;text-decoration:underline">Description</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:7.75pt"><font style="color:#0066cc;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">99.1</font><font style="color:#0066cc;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit991-260512.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Press Release dated May 12, 2026</a></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icf35b237d85642fa97794bbe6e25ca5c_4"></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.55pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.55pt;padding-right:14.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:280.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">INNATE PHARMA S.A.</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:280.1pt;padding-right:5.8pt;text-indent:-274.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:125%">Date&#58; May 12, 2026&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47; JONATHAN DICKINSON&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:125%"> Name&#58;&#160;&#160;&#160;&#160;Jonathan Dickinson</font></div><div style="padding-left:333.15pt;text-indent:-53.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9.05pt;font-weight:400;line-height:9.05pt">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="margin-top:0.45pt;padding-left:247.85pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991-260512.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i3e6ab0b360bc4577a3366f8fad3d1077_1"></div><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.4pt;padding-right:5.45pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">EXHIBIT 99.1</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Number of shares and voting rights of Innate Pharma as of April 16, 2026</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marseille, France, May 12, 2026, 7&#58;00 A.M. CEST</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the article L. 233-8 II of the French &#8220;Code de Commerce&#8221; and the article 223-16 of the French stock-market authorities (Autorit&#233; des March&#233;s Financiers, or &#8220;AMF&#8221;) General Regulation, Innate Pharma SA (Euronext Paris&#58; IPH&#59; Nasdaq&#58; IPHA) (&#8220;Innate&#8221; or the &#8220;Company&#8221;) releases its total number of shares outstanding as well as its voting rights as of April 16, 2026&#58;</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total number of shares outstanding&#58; 93,934,210 shares</font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including &#58; 93,921,863 ordinary shares</font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,766 Preferred Shares 2016</font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,581 Preferred Shares 2017</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total number of theoretical voting rights (1)&#58; 93,921,863</font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total number of exercisable voting rights (2)&#58; 93,903,288&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">(1) The total number of theoretical voting rights (or &#8220;gross&#8221; voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. No voting rights attached to AGAP 2016 and AGAP 2017.</font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">(2) The total number of exercisable voting rights (or &#8220;net&#8221; voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">About Innate Pharma&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.  </font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma is advancing a portfolio of differentiated potential first and&#47;or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer. </font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.  </font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. </font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.&#8239;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Information about Innate Pharma shares&#58;</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">ISIN code&#58; FR0010331421</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Ticker code&#58; Euronext&#58; IPH Nasdaq&#58; IPHA</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">LEI&#58; 9695002Y8420ZB8HJE29</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Disclaimer on forward-looking information and risk factors&#58; </font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For a discussion of risks and uncertainties, please refer to the Risk Factors (&#8220;Facteurs&#160;de Risque&#34;) section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website&#160;(</font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;www.amf-france.org)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;or on Innate Pharma&#8217;s website</font><font style="color:#d13438;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(www.innate-pharma.com)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, and public filings </font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company&#8217;s website and the AMF website are included for information&#160;only&#160;and the content&#160;contained&#160;therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This press release and the information&#160;contained&#160;herein&#160;do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.&#160;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">For additional information, please contact&#58;</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Investors &#38; Media Relations</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innate Pharma&#160;</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">St&#233;phanie Cornen&#160;</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stephanie.cornen&#64;innate-pharma.fr&#160;</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Relations</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investors&#64;innate-pharma.fr&#160;</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media</font></div><div style="margin-bottom:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">communication&#64;innate-pharma.fr</font><font style="color:#0000ff;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
